Vallon Faustine, Meier Christoph, Gautier Emanuel, Wahl Peter
Division of Orthopeadics and Traumatology, Cantonal Hospital Winterthur, 8401 Winterthur, Switzerland.
Department of Orthopaedics, HFR Fribourg-Cantonal Hospital, 1752 Fribourg, Switzerland.
J Clin Med. 2022 Aug 20;11(16):4900. doi: 10.3390/jcm11164900.
Local application of antibiotics with calcium-containing carrier materials (CCCM) might deliver large quantities of calcium, with some cases of hypercalcaemia reported. The incidence of symptomatic hypercalcaemia was estimated retrospectively in a consecutive, prospective series of patients treated between 10/2006 and 02/2019 with antibiotic-loaded CCCM for various orthopaedic infections. Risk factors were analysed. In the study period, 215 CCCM applications were performed. Two patients (0.9%) developed symptomatic hypercalcaemia. In one case, hypercalcaemia occurred 14 days after a second CCCM application during a staged septic hip revision. In the other case, hypercalcaemia became symptomatic six days after application of vancomycin-loaded CCCM in a component-retaining septic revision hip arthroplasty. In both cases, hypercalcemia was not imputable solely to the CCCM. Prolonged immobilization, renal impairment and other specific risk factors were present. Implantation of a CCCM for local application of antibiotics exposes the patient to large quantities of calcium during dissolution. This might induce symptomatic hypercalcaemia, a potentially life-threatening complication. The observed incidence of symptomatic hypercalcaemia remained rare (<1%). In some patients, compensatory mechanisms might be overwhelmed in the presence of other risk factors. Postoperative monitoring of calcaemia as well as elimination of risk factors is mandatory for all patients treated with CCCM.
将含抗生素的含钙载体材料(CCCM)局部应用可能会输送大量钙,已有一些高钙血症病例的报道。对2006年10月至2019年2月期间连续、前瞻性系列接受CCCM负载抗生素治疗各种骨科感染的患者进行回顾性估计有症状性高钙血症的发生率。分析了危险因素。在研究期间,进行了215次CCCM应用。两名患者(0.9%)出现有症状性高钙血症。一例中,在分期性化脓性髋关节翻修术中第二次应用CCCM后14天发生高钙血症。另一例中,在保留假体的化脓性翻修髋关节置换术中应用万古霉素负载的CCCM后6天高钙血症出现症状。在这两例中,高钙血症并非完全归因于CCCM。存在长期制动、肾功能损害和其他特定危险因素。植入用于局部应用抗生素的CCCM在溶解过程中会使患者暴露于大量钙中。这可能会诱发有症状性高钙血症,一种潜在的危及生命的并发症。观察到的有症状性高钙血症的发生率仍然很低(<1%)。在一些患者中,在存在其他危险因素的情况下,代偿机制可能会不堪重负。对于所有接受CCCM治疗的患者,术后监测血钙以及消除危险因素是必不可少的。